Farmas USA

Ultimamente para m/saca, estoy a la caza de aquellas que reunan los siquientes requisitos 

Market Cap + de 500 M de preferencia aunque chicharreo permitido si es muy  golosa la invitacion

RSI semanal y diario en sobreventa 

Short Interest decreciente en los dos ultimos reportes o al menos no en aumento , 

News y/o  valoraciones de analistas que justifiquen un rebote interesante 

**

Se aceptan colaboradores / Criticas/  Comentarios y mas 

Aseguro que en un % interesante se consigue exprimir a la mayoria de las que cumplen los requsitos 

GILD

Gilead o la historia de la increible facturación menguante...

Gilead Q2 revenues down 21%; earnings down 41%; shares down 2% after hours

https://seekingalpha.com/news/3373645-gilead-q2-revenues-21-percent-earnings-41-percent-shares-2-percent-hours

Gilead Sciences (GILD) Q2 results ($M):

Revenues: 5,648 (-20.9%); Product sales: 5,540 (-21.4%).

Net income: 1,817 (-40.9%); non-GAAP net income: 2,494 (-26.0%); EPS: 1.39 (-40.3%); non-GAAP EPS: 1.91 (-25.4%).

2018 guidance: Product sales: $20B - 21B (unch).

Key product sales: Genvoya: 1,160 (+35.4%); Truvada: 765 (-5.8%); Epclusa: 500 (-57.3%); Harvoni: 331 (-76.0%); Vosevi: 109; Descovy: 403 (+40.9%); Odefsey: 385 (+49.2%); Biktarvy: 185; Vosevi: 109; Yescarta: 68.

GILD

Y no sé si directamente relacionado con la incapacidad para encontrar nuevas fuentes de ingresos (es probable que así sea), el CEO anuncia retirada después de 28 años en la empresa...

Gilead chief Milligan to step down at year-end

https://seekingalpha.com/news/3373672-gilead-chief-milligan-step-year-end

Los osos parece que .... o gozan de informacion privilegada o tiene demasiado buen olfato 

GILD   Short % Increase + 12 %

BIIB que palma en after
GILD que vaya ER que se ha cascado
Y el sector ya se le veia con pocas ganas de verde... Veras tu mañana...

Biotech Stocks Are Tariff-Safe And Building Momentum

The Nasdaq Biotechnology Index is poised to make a 52-week high and most likely an all-time high shortly thereafter.

Biotech stocks are more insulated from the biggest concern for the market - the tariffs - than most industries.

The rapid pace of new advancements continues to maintain the excitement for biotechs.

Biotech is poised to outperform broader indexes in the third quarter even though it will begin to face growing political rhetoric on drug prices as the November mid-term elections approach.

The Prudent Biotech portfolio was up +51% in the first half. Promising opportunities will remain in the second half, even though trade friction is a growing risk for the broader market.

https://seekingalpha.com/article/4189138-biotech-stocks-tariff-safe-building-momentum

Cannabinoids May Do More Than Manage Cancer Symptoms -- CFN Media

The liberalization of cannabis laws around the world has opened the door for researchers to explore the therapeutic benefits of cannabinoids. While GW Pharmaceuticals plc ( GWPH) has already launched products targeting epilepsy and spasticity in Multiple Sclerosis, emerging research suggests that they could play a role in treating many types of cancers.

https://finance.yahoo.com/news/cannabinoids-may-more-manage-cancer-130000981.html

Vistas las castañas de sesiones que lleva últimamente, parece claro que se va a ir mas abajo. La espero en 6,20 aprox. Y eso que estoy dentro desde bastante más arriba.

AKAO